Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Calamos Advisors LLC

Marco Green
March 13, 2018

Therefore 74% are positive. Steris had 11 analyst reports since November 2, 2015 according to SRatingsIntel. Raymond James has "Outperform" rating and $95 target. The company was initiated on Wednesday, March 1 by Citigroup. Raymond James maintained it with "Outperform" rating and $100 target in Monday, October 16 report. The firm has "Perform" rating by Oppenheimer given on Thursday, December 15. Analysts are turning out to be more optimistic than before, with 23 of analysts who cover UnitedHealth Group Incorporated (NYSE:UNH) advice adding it to buy candidate list. H.C. Wainwright downgraded the stock to "Neutral" rating in Monday, October 24 report. As per Wednesday, March 1, the company rating was initiated by Citigroup.

Hightower Advisors Llc decreased its stake in Vertex Pharmaceuticals Inc (VRTX) by 15.75% based on its latest 2017Q3 regulatory filing with the SEC. Lucas Capital holds 0.27% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 2,015 shares. The Atalanta Sosnoff Capital Llc holds 389,601 shares with $59.24 million value, up from 288,084 last quarter. By 2019, we can expect Vertex Pharmaceuticals's bottom line to reach US$457.74M, a jump from the current US$263.19M. The stock increased 0.73% or $1.29 during the last trading session, reaching $177.55. About 761,727 shares traded.

Barings LLC acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 4th quarter, according to its most recent 13F filing with the SEC. It has outperformed by 28.99% the S&P500. When looking at the past five sessions, the stock returned 0.11% gains and is up by 9.43% compared with its 200-day moving average of $215.05. Meritor, Inc. (MTOR) has risen 104.71% since March 12, 2017 and is uptrending. It has underperformed by 8.73% the S&P500.

Investors sentiment increased to 1.53 in Q3 2017. Its down 0.28, from 1.62 in 2017Q2. Quantitative Systematic Strategies reported 2,480 shares. Invesco reported 0% stake. Castleark Mngmt Limited Liability Corp accumulated 26,830 shares. Keybank National Association Oh has 4,514 shares for 0% of their portfolio. Federated Investors Inc Pa owns 51,286 shares or 0.02% of their USA portfolio. Jefferies Gru Ltd Liability reported 34,300 shares. James Investment invested in 44,220 shares. Rhumbline Advisers reported 0% of its portfolio in Connecticut Water Service, Inc.

STERIS plc develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support services and products for healthcare, pharmaceutical, scientific, research, industrial, and governmental clients worldwide. The company has market cap of $44.75 billion. The Water Operations segment supplies public drinking water. The price/earnings ratio (P/E) is 169.81 and the forward P/E ratio stands at 38.77. It also provides OR integration, OR and sterile processing department, workflow, patient tracking, and instrument management solutions; and cleaning chemistries and sterility assurance products. It also upped Emerson Electric Co (NYSE:EMR) stake by 92,909 shares and now owns 107,185 shares. Tripadvisor Inc (Call) (NASDAQ:TRIP) was reduced too.

Investors sentiment decreased to 1.34 in Q3 2017. The share price has yet to cross its 20 days moving average, floating at a distance of -0.51% and sits -1.87% lower versus its 50 days moving average. It dived, as 32 investors sold Vertex Pharmaceuticals Incorporated shares while 151 reduced holdings. Finally, First Quadrant L P CA raised its position in shares of Vertex Pharmaceuticals by 6,526.6% during the third quarter. The pharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.53 by $0.08. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since March 11, 2017 and is uptrending. Tokio Marine Asset Mgmt owns 2,132 shares or 0.05% of their USA portfolio.

Towle & Co holds 7.11% of its portfolio in Meritor, Inc. for 2.57 million shares. Elk Creek Limited Com owns 3,392 shares. Jpmorgan Chase & Com accumulated 0.31% or 9.32 million shares. Amer Rech & Mgmt Company stated it has 8,950 shares or 0.44% of all its holdings.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. Prudential Fincl Incorporated owns 0.09% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 346,585 shares. Assetmark invested 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Martingale Asset Lp holds 0.03% or 14,305 shares. 13,886 were reported by Eqis Inc. Profund Lc has invested 0.77% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). VRTX's profit will be $68.55M for 163.20 P/E if the $0.27 EPS becomes a reality. During the same quarter in the previous year, the company posted $0.35 earnings per share. Therefore 87% are positive.

Vertex Pharmaceuticals announced that its board has approved a share buyback plan on Wednesday, January 31st that permits the company to buyback $500.00 million in shares. The rating was maintained by RBC Capital Markets on Wednesday, October 18 with "Buy". Leerink Swann restated an "outperform" rating and set a $190.00 price objective (up from $175.00) on shares of Vertex Pharmaceuticals in a report on Thursday, February 1st. The company was upgraded on Thursday, January 26 by Stifel Nicolaus. Morgan Stanley maintained the stock with "Overweight" rating in Friday, February 2 report. The firm has "Buy" rating given on Tuesday, January 2 by BMO Capital Markets.

Since October 2, 2017, it had 0 buys, and 45 selling transactions for $121.15 million activity. The insider MCGLYNN MARGARET G sold $3.25 million. Chodakewitz Jeffrey sold 1,719 shares worth $270,358. $336,345 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Arbuckle Stuart A on Tuesday, January 16. Following the completion of the transaction, the senior vice president now directly owns 17,923 shares of the company's stock, valued at approximately $2,729,852.13. New York State Teachers Retirement System stated it has 0.15% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). 12,682 shares were sold by WOMBLE DUSTIN R, worth $2.32M on Monday, December 11.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article